GAIN TOOLS Act of 2022

Bill: 117-s-3478
Sponsor: full_name: Sen. Casey, Robert P., Jr. [D-PA]
Introduced: 2022-01-11
Policy area: Health
Latest action: action_date: 2022-01-11
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2022-01-11
action_desc: Introduced in Senate
text: <p><strong>Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022</strong></p> <p>This bill expands the definition of a qualified infectious disease product (QIDP) to include eligible biological products. Under current law, the first application (or supplement) for a specific product and indication to be designated a QIDP shall receive priority review for market approval by the Food and Drug Administration. </p> <p>Generally, a biological product designated as a QIDP is one that acts on bacteria or fungi and is intended to treat a serious or life-threatening infection.</p> <p>However, a biological product with a QIDP designation shall not receive the market exclusivity extension currently available to drugs that receive the designation.</p>

tv_txt: II 117th CONGRESS 2d Session S. 3478 IN THE SENATE OF THE UNITED STATES January 11 (legislative day, January 10), 2022 Mr. Casey (for himself, Mr. Cassidy , and Mr. Murphy ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To provide for the designation of biological products as qualified infectious disease products.

1. Short title This Act may be cited as the Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022 . 2. Expanding qualified infectious disease products to include biological products (a) In general Section 505E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355f ) is amended— (1) in subsection (c)— (A) in paragraph (2), by striking ; or and inserting ; ; (B) in paragraph (3), by striking the period and inserting ; or ; and (C) by adding at the end the following: (4) an application pursuant to section 351(a) of the Public Health Service Act. ; (2) in subsection (d)(1), by inserting of this Act or section 351(a) of the Public Health Service Act after section 505(b) ; and (3) by amending subsection (g) to read as follows: (g) Qualified infectious disease product The term qualified infectious disease product means a drug or biological product for human use that— (1) is— (A) an antibacterial or antifungal drug; or (B) a biological product that acts directly on bacteria or fungi or on substances produced by such bacteria or fungi; and (2) is intended to treat a serious or life-threatening infection, including such an infection caused by— (A) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or (B) qualifying pathogens listed by the Secretary under subsection (f). . (b) Priority review Section 524A(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360n–1(a) ) is amended by inserting of this Act, or section 351(a) of the Public Health Service Act, that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness before the period.